Jagsonpal Pharmaceuticals Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹59Cr
- +37.2% YoY
- −20.3% QoQ
- Net profit
- ₹7Cr
- +75% YoY
- −78.1% QoQ
- Margin
- 15%
- +9 pp YoY
- −6 pp QoQ
Guidance rank: #54 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Jagsonpal Pharmaceuticals Ltd Q4 FY25 key numbers
- Revenue
- Growth driven by improved medical rep productivity (currently INR2 to 2.1 lakhs PCPM) with aspiration to increase productivity by 50% over 3-4 years.
As stated in Jagsonpal Pharmaceuticals Ltd's Q4 FY25 earnings call transcript · published 15 Jul 2026. Reported figures, not investment advice.
The short version
Target organic growth: 12% to 15% per year going forward, improving from 8% in FY25. The company aspires to achieve a 15% revenue growth rate internally.
From Jagsonpal Pharmaceuticals Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Target organic growth: 12% to 15% per year going forward, improving from 8% in FY25.
- Inorganic growth not forecasted due to unpredictability of acquisitions.
- Growth driven by improved medical rep productivity (currently INR2 to 2.1 lakhs PCPM) with aspiration to increase productivity by 50% over 3-4 years.
- Sales growth impacted by product mix changes; volumes have been flat due to decline in specific franchises like Dydrogesterone.
- Launching 4 to 6 new products annually, mainly extensions and some new molecules.
2 more points from Jagsonpal Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jagsonpal Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Jagsonpal Pharmaceuticals follows an asset-light model with no own manufacturing; all products for India are produced using CMOs.
- The company has no significant capex plans for building plants or machinery.
- Investment is primarily in computer infrastructure and office/field force technology.
- Real capital investment focus is on acquisitions – primarily brand or business acquisitions fitting strategic therapeutic areas.
- The company remains disciplined on acquisitions, focusing on fair valuations and value addition for shareholders.
- If suitable acquisition targets are not found, surplus cash will be returned to shareholders instead of spending on overpriced or non-strategic deals.
2 more points from Jagsonpal Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jagsonpal Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Jagsonpal Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit
Jagsonpal Pharmaceuticals Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 59 | 43 | +37.2% | 74 | -20.3% |
| Operating profit (EBITDA) | 9 | 3 | +200% | 16 | -43.7% |
| Operating margin | 15% | 6% | +9 pp | 21% | -6 pp |
| Profit before tax | 9 | 5 | +80% | 39 | -76.9% |
| Net profit (PAT) | 7 | 4 | +75% | 32 | -78.1% |
| EPS (₹) | 0.99 | 0.54 | +83.3% | 4.82 | -79.5% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹81 Cr, net profit ₹13 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jagsonpal Pharma's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jagsonpal Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jagsonpal Pharmaceuticals Ltd Q4 FY25 results?
Target organic growth: 12% to 15% per year going forward, improving from 8% in FY25. The company aspires to achieve a 15% revenue growth rate internally.
What is Jagsonpal Pharmaceuticals Ltd share price analysis?
Jagsonpal Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?
Jagsonpal Pharmaceuticals follows an asset-light model with no own manufacturing; all products for India are produced using CMOs.
Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
